Abstract
Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.
| Original language | English |
|---|---|
| Journal | Haematologica |
| Volume | 108 |
| Issue number | 1 |
| Pages (from-to) | 22-33 |
| Number of pages | 12 |
| ISSN | 0390-6078 |
| DOIs | |
| Publication status | Published - 2023 |
Bibliographical note
Publisher Copyright:©2023 Ferrata Storti Foundation.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
COVID-19 in adult acute myeloid leukemia patients : a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). / Marchesi, Francesco; Salmanton-García, Jon; Emarah, Ziad; Piukovics, Klára; Nucci, Marcio; López-García, Alberto; Ráčil, Zdeněk; Farina, Francesca; Popova, Marina; Zompi, Sofia; Audisio, Ernesta; Ledoux, Marie Pierre; Verga, Luisa; Weinbergerová, Barbora; Szotkovski, Tomas; Da Silva, Maria Gomes; Fracchiolla, Nicola; De Jonge, Nick; Collins, Graham; Marchetti, Monia; Magliano, Gabriele; García-Vidal, Carolina; Biernat, Monika M.; Van Doesum, Jaap; Machado, Marina; Demirkan, Fatih; Al-Khabori, Murtadha; Žák, Pavel; Víšek, Benjamín; Stoma, Igor; Méndez, Gustavo Adolfo; Maertens, Johan; Khanna, Nina; Espigado, Ildefonso; Dragonetti, Giulia; Fianchi, Luana; Del Principe, Maria Ilaria; Cabirta, Alba; Ormazabal-Vélez, Irati; Jaksic, Ozren; Buquicchio, Caterina; Bonuomo, Valentina; Batinić, Josip; Omrani, Ali S.; Lamure, Sylvain; Finizio, Olimpia; Fernández, Noemí; Falces-Romero, Iker; Blennow, Ola; Bergantim, Rui; Ali, Natasha; Win, Sein; Van Praet, Jens; Tisi, Maria Chiara; Shirinova, Ayten; Schönlein, Martin; Prattes, Juergen; Piedimonte, Monica; Petzer, Verena; Navrátil, Milan; Kulasekararaj, Austin; Jindra, Pavel; Sramek, Jiří; Glenthøj, Andreas; Fazzi, Rita; De Ramón-Sánchez, Cristina; Cattaneo, Chiara; Calbacho, Maria; Bahr, Nathan C.; El-Ashwah, Shaimaa; Cordoba, Raul; Hanakova, Michaela; Zambrotta, Giovanni Paolo Maria; Zambrotta, Giovanni; Sciumè, Mariarita; Booth, Stephen; Rodrigues, Raquel Nunes; Sacchi, Maria Vittoria; García-Poutón, Nicole; Martín-González, Juan Alberto; Khostelidi, Sofya; Gräfe, Stefanie; Rahimli, Laman; Ammatuna, Emanuele; Busca, Alessandro; Corradini, Paolo; Hoenigl, Martin; Klimko, Nikolai; Koehler, Philipp; Pagliuca, Antonio; Passamonti, Francesco; Cornely, Oliver A.; Pagano, Livio.
In: Haematologica, Vol. 108, No. 1, 2023, p. 22-33.Research output: Contribution to journal › Journal article › Research › peer-review
}
TY - JOUR
T1 - COVID-19 in adult acute myeloid leukemia patients
T2 - a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
AU - Marchesi, Francesco
AU - Salmanton-García, Jon
AU - Emarah, Ziad
AU - Piukovics, Klára
AU - Nucci, Marcio
AU - López-García, Alberto
AU - Ráčil, Zdeněk
AU - Farina, Francesca
AU - Popova, Marina
AU - Zompi, Sofia
AU - Audisio, Ernesta
AU - Ledoux, Marie Pierre
AU - Verga, Luisa
AU - Weinbergerová, Barbora
AU - Szotkovski, Tomas
AU - Da Silva, Maria Gomes
AU - Fracchiolla, Nicola
AU - De Jonge, Nick
AU - Collins, Graham
AU - Marchetti, Monia
AU - Magliano, Gabriele
AU - García-Vidal, Carolina
AU - Biernat, Monika M.
AU - Van Doesum, Jaap
AU - Machado, Marina
AU - Demirkan, Fatih
AU - Al-Khabori, Murtadha
AU - Žák, Pavel
AU - Víšek, Benjamín
AU - Stoma, Igor
AU - Méndez, Gustavo Adolfo
AU - Maertens, Johan
AU - Khanna, Nina
AU - Espigado, Ildefonso
AU - Dragonetti, Giulia
AU - Fianchi, Luana
AU - Del Principe, Maria Ilaria
AU - Cabirta, Alba
AU - Ormazabal-Vélez, Irati
AU - Jaksic, Ozren
AU - Buquicchio, Caterina
AU - Bonuomo, Valentina
AU - Batinić, Josip
AU - Omrani, Ali S.
AU - Lamure, Sylvain
AU - Finizio, Olimpia
AU - Fernández, Noemí
AU - Falces-Romero, Iker
AU - Blennow, Ola
AU - Bergantim, Rui
AU - Ali, Natasha
AU - Win, Sein
AU - Van Praet, Jens
AU - Tisi, Maria Chiara
AU - Shirinova, Ayten
AU - Schönlein, Martin
AU - Prattes, Juergen
AU - Piedimonte, Monica
AU - Petzer, Verena
AU - Navrátil, Milan
AU - Kulasekararaj, Austin
AU - Jindra, Pavel
AU - Sramek, Jiří
AU - Glenthøj, Andreas
AU - Fazzi, Rita
AU - De Ramón-Sánchez, Cristina
AU - Cattaneo, Chiara
AU - Calbacho, Maria
AU - Bahr, Nathan C.
AU - El-Ashwah, Shaimaa
AU - Cordoba, Raul
AU - Hanakova, Michaela
AU - Zambrotta, Giovanni Paolo Maria
AU - Zambrotta, Giovanni
AU - Sciumè, Mariarita
AU - Booth, Stephen
AU - Rodrigues, Raquel Nunes
AU - Sacchi, Maria Vittoria
AU - García-Poutón, Nicole
AU - Martín-González, Juan Alberto
AU - Khostelidi, Sofya
AU - Gräfe, Stefanie
AU - Rahimli, Laman
AU - Ammatuna, Emanuele
AU - Busca, Alessandro
AU - Corradini, Paolo
AU - Hoenigl, Martin
AU - Klimko, Nikolai
AU - Koehler, Philipp
AU - Pagliuca, Antonio
AU - Passamonti, Francesco
AU - Cornely, Oliver A.
AU - Pagano, Livio
N1 - Publisher Copyright: ©2023 Ferrata Storti Foundation.
PY - 2023
Y1 - 2023
N2 - Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.
AB - Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.
UR - http://www.scopus.com/inward/record.url?scp=85136991749&partnerID=8YFLogxK
U2 - 10.3324/haematol.2022.280847
DO - 10.3324/haematol.2022.280847
M3 - Journal article
C2 - 35545919
AN - SCOPUS:85136991749
VL - 108
SP - 22
EP - 33
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 1
ER -